nach oben

Erschienen in:

02.06.2016 | Hepatobiliary-Pancreas

Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis

verfasst von: Katsuhiro Sano, Tomoaki Ichikawa, Utaroh Motosugi, Shintaro Ichikawa, Hiroyuki Morisaka, Nobuyuki Enomoto, Masanori Matsuda, Hideki Fujii

Erschienen in: European Radiology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the longitudinal risk to patients with cirrhosis of hypervascular hepatocellular carcinoma (HCC) developing from hypovascular hepatic nodules that show positive uptake of gadoxetic acid (hyperintensity) on hepatocyte phase images.

Methods

In 69 patients, we evaluated findings from serial follow-up examinations of 633 hepatic nodules that appeared hypovascular and hyperintense on initial gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) until the nodules demonstrated hypervascularity and were diagnosed as hypervascular HCC. Cox analyses were performed to identify risk factors for the development of hypervascular HCCs from the nodules.

Results

The median follow-up was 663 days (range, 110 to 1215 days). Hypervascular HCCs developed in six of the 633 nodules (0.9 %) in five of the 69 patients. The only independent risk factor, the nodule’s initial maximum diameter of 10 mm or larger, demonstrated a hazard ratio of 1.25. The one-year risk of hypervascular HCC developing from a nodule was 0.44 %. The risk was significantly higher for nodules of larger diameter (1.31 %) than those smaller than 10 mm (0.10 %, p < 0.01).

Conclusions

Hypervascular HCC rarely develops from hypovascular, hyperintense hepatic nodules. We observed low risk even for nodules of 10 mm and larger diameter at initial examination.

Key Points

• Hypervascularization was rare on follow-up examination of hypovascular, hyperintense nodules

• The risk of hypervascularization in a nodule increased with large size

• Hypovascular, hyperintense nodules require neither treatment nor more intense follow-up

International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology 49:658–664CrossRef

Takayama T, Makuuchi M, Hirohashi S et al (1990) Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 336:1150–1153CrossRefPubMed

Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y (2009) Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation. Radiology 252:605–614CrossRefPubMed

Huppertz A, Haraida S, Kraus A et al (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. Radiology 234:468–478CrossRefPubMed

Motosugi U, Ichikawa T, Sou H et al (2010) Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256:151–158CrossRefPubMed

Jung G, Breuer J, Poll LW et al (2006) Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 47:15–23CrossRefPubMed

Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931CrossRefPubMed

Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466CrossRefPubMed

Motosugi U, Ichikawa T, Araki T (2013) Rules, roles, and room for discussion in gadoxetic acid-enhanced magnetic resonance liver imaging: current knowledge and future challenges. Magn Reson Med Sci 12:161–175CrossRefPubMed

10.

Inoue T, Kudo M, Komuta M et al (2012) Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 47:1036–1047CrossRefPubMed

11.

Ichikawa T, Saito K, Yoshioka N et al (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Investig Radiol 45:133–141CrossRef

12.

Golfieri R, Grazioli L, Orlando E et al (2012) Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging 36:648–657CrossRefPubMed

13.

Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261:834–844CrossRefPubMed

14.

Motosugi U, Ichikawa T, Sano K et al (2011) Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 34:88–94CrossRefPubMed

15.

Kumada T, Toyoda H, Tada T et al (2011) Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 197:58–63CrossRefPubMed

16.

Hyodo T, Murakami T, Imai Y et al (2013) Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 266:480–490CrossRefPubMed

17.

Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D (2012) Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 265:104–114CrossRefPubMed

18.

Kim YS, Song JS, Lee HK, Han YM (2015) Hypovascular hypointense nodules on hepatobiliary phase without T2 hyperintensity on gadoxetic acid-enhanced MR images in patients with chronic liver disease: long-term outcomes and risk factors for hypervascular transformation. Eur Radiol. doi:10.1007/s00330-015-4146-9

19.

Higaki A, Ito K, Tamada T et al (2014) Prognosis of small hepatocellular nodules detected only at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging as hypointensity in cirrhosis or chronic hepatitis. Eur Radiol 24:2476–2481CrossRefPubMed

20.

Chen N, Motosugi U, Sano K et al (2013) Early hepatocellular carcinomas showing isointensity or hyperintensity in gadoxetic acid-enhanced, hepatocyte-phase magnetic resonance images. J Comput Assist Tomogr 37:466–469CrossRefPubMed

21.

Kanata N, Yoshikawa T, Ohno Y et al (2013) HCC-to-liver contrast on arterial-dominant phase images of EOB-enhanced MRI: comparison with dynamic CT. Magn Reson Imaging 31:17–22CrossRefPubMed

22.

Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y (2014) Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. Oncology 87:7–21CrossRefPubMed

23.

Imai Y, Murakami T, Hori M et al (2008) Hypervascular hepatocellular carcinoma: combined dynamic MDCT and SPIO-enhanced MRI versus combined CTHA and CTAP. Hepatol Res 38:147–158PubMed

24.

Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral

25.

European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef

26.

Murakami T, Oi H, Hori M et al (1997) Helical CT during arterial portography and hepatic arteriography for detecting hypervascular hepatocellular carcinoma. AJR Am J Roentgenol 169:131–135CrossRefPubMed

27.

Matsui O, Takashima T, Kadoya M et al (1985) Dynamic computed tomography during arterial portography: the most sensitive examination for small hepatocellular carcinomas. J Comput Assist Tomogr 9:19–24CrossRefPubMed

28.

Miyayama S, Matsui O, Yamashiro M et al (2009) Detection of hepatocellular carcinoma by CT during arterial portography using a cone-beam CT technology: comparison with conventional CTAP. Abdom Imaging 34:502–506CrossRefPubMed

29.

Merine D, Takayasu K, Wakao F (1990) Detection of hepatocellular carcinoma: comparison of CT during arterial portography with CT after intraarterial injection of iodized oil. Radiology 175:707–710CrossRefPubMed

30.

Van Beers BE, Pastor CM, Hussain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57:421–429CrossRefPubMed

31.

Bartolozzi C, Battaglia V, Bargellini I et al (2013) Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 38:290–296CrossRefPubMed

32.

Yoshida H, Shiratori Y, Moriyama M et al (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131:174–181CrossRefPubMed

33.

Tsukuma H, Hiyama T, Tanaka S et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801CrossRefPubMed

34.

Motosugi U, Bannas P, Sano K, Reeder SB (2015) Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J Magn Reson Imaging 41:251–265CrossRefPubMed

35.

Tsuboyama T, Onishi H, Kim T et al (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824–833CrossRefPubMed

36.

Kitao A, Zen Y, Matsui O et al (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging--correlation with molecular transporters and histopathologic features. Radiology 256:817–826CrossRefPubMed

37.

Kitao A, Matsui O, Yoneda N et al (2012) Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 265:780–789CrossRefPubMed

38.

Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker. Radiology 267:776–786CrossRefPubMed

39.

Beasley RP, Hwang LY, Lin CC, Chien CS (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 2:1129–1133CrossRefPubMed

40.

Liang TJ, Jeffers LJ, Reddy KR et al (1993) Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 18:1326–1333PubMed

41.

Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M (2008) Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2:17–30CrossRefPubMed

42.

Chang KC, Lu SN, Chen PF et al (2011) Incidence and associated risk factors of hepatocellular carcinoma in a dural hepatitis B and C virus endemic area: a surveillance study. Kaohsiung J Med Sci 27:85–90CrossRefPubMed

43.

Lok AS, Seeff LB, Morgan TR et al (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136:138–148CrossRefPubMed

Titel: Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis
verfasst von: Katsuhiro Sano
Tomoaki Ichikawa
Utaroh Motosugi
Shintaro Ichikawa
Hiroyuki Morisaka
Nobuyuki Enomoto
Masanori Matsuda
Hideki Fujii
Publikationsdatum: 02.06.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 2/2017
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-016-4423-2

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis